secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001213900-24-044798
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma terminates land transfer agreement with director Shuling Jiang
-----------------------------------------------------------------------------

- Board terminated agreement to acquire land in Taoyuan City, Taiwan from director Shuling Jiang on May 16, 2024.
- Jiang is a director, married to Chief Strategic Officer, and owns ~10% of ABVC common stock.
- Company may reconsider the transaction at a later date; no penalty or financial impact disclosed.
- Original agreement was reported on Feb 8, 2024; termination is effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/0001213900-24-044798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024044798/ea020639401-8ka_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-044798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer